Corcept (CORT) Upgraded After Key Regulatory Approval for Lifyorli

Corcept Therapeutics Incorporated (NASDAQ:CORT) ranks among the most profitable biotech stocks to buy now. At the Society of Gynecologic Oncology Annual Meeting on April 10, Corcept Therapeutics Incorporated (NASDAQ:CORT) reported the conclusive total survival results from its Phase 3 ROSELLA study of Lifyorli in combination with nab-paclitaxel for platinum-resistant ovarian cancer.

The FDA had approved Lifyorli for the treatment of individuals with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have had up to three prior systemic therapies, at least one of which included bevacizumab.

Based on the results of the study, patients who received Lifyorli in addition to nab-paclitaxel had a 35% lower risk of dying than those who only received nab-paclitaxel. Additionally, compared to nab-paclitaxel monotherapy, the combination showed a 30% lower risk of disease progression.

Following FDA approval, Wolfe Research boosted Corcept Therapeutics Incorporated (NASDAQ:CORT) to Peerperform from Underperform. The firm sees the approval as eliminating a key downside prospect for the stock. Nonetheless, Wolfe questions the long-term viability of Corcept’s main Cushing’s disease franchise.

Corcept Therapeutics Incorporated (NASDAQ:CORT), incorporated in 1998, is a California-based biopharmaceutical company that discovers and develops solutions for serious endocrinologic, oncologic, metabolic, and neurologic disorders.

While we acknowledge the risk and potential of CORT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CORT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.